On October 30, 2024 Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, reported first-in-human clinical data for its lead selective T cell activator, invikafusp alfa (STAR0602), will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 39th Annual Meeting taking place November 8-10th, 2024 in Houston, Texas (Press release, Marengo Therapeutics, OCT 30, 2024, View Source [SID1234647554]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Title: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
Conference: 39th SITC (Free SITC Whitepaper) Annual Meeting
Abstract Number: LBA-1470
Session Title: Late-Breaking Abstract Session 2
Session Date and Time: Saturday, November 9, 2024, 11:45 AM – 12:15 PM
Presenter: James L. Gulley, M.D., Ph.D. (National Cancer Institute, Bethesda, Maryland, USA)